The Best Bad Deal of All Time? Pfizer/King and the Business Dynamics of Abuse Deterrence
This article was originally published in RPM Report
Executive Summary
Pfizer’s acquisition of King gave the company a chance to play in a new kind of market: abuse deterrent opioid pain relief formulations. Two years later, Pfizer is moving in the other direction, even as FDA’s actions validate the notion that there is an opportunity—and that the scale of Big Pharma can play a critical role.
You may also be interested in...
Abuse-Deterrent Opioids: Where Are They Now?
The potential blockbuster category for abuse-deterrent opioids has fizzled. A few stalwarts are pushing on, but the return on investment for many drug manufacturers has been disappointing. Scrip tracked how opioids approved in the last eight years have performed.
KemPharm And The Curious Case Of Launching A Brand Opioid Like A Generic
KemPharm is looking to sign a generic drug partner to launch its new brand opioid Apadaz, which says a lot about how the commercial promise of abuse-deterrent opioids has so far failed to materialize.
KemPharm And The Curious Case Of Launching A Brand Opioid Like A Generic
KemPharm is looking to sign a generic drug partner to launch its new brand opioid Apadaz, which says a lot about how the commercial promise of abuse-deterrent opioids has so far failed to materialize.